Skip to main content

Table 1 Characteristics of biliary tract cancer patients

From: Comparison of the effects of adjuvant concurrent chemoradiotherapy and chemotherapy for resected biliary tract cancer

Characteristic Total (n = 92) Adjuvant CCRT (n = 46) Adjuvant chemotherapy (n = 46) P value
Median age, years (range) 64.5 (34–81) 65.5 (44–81) 61.0 (34–80) 0.134
Men (%) 58 (63.0) 26 (56.5) 32 (69.6) 0.195
Performance (%)
 KPS ≥70 83 (90.2) 41 (89.1) 42 (91.3) 1.000
 KPS < 70 9 (9.8) 5 (10.9) 4 (8.7)
Comorbidities (%)
 CCI < 3 50 (54.3) 24 (52.2) 26 (56.5) 0.675
 CCI ≥3 42 (45.7) 22 (47.8) 20 (43.5)
Tumor location (%)
 Intrahepatic bile duct 13 (14.1) 6 (13.0) 7 (15.2) 0.756
 Perihilar bile duct 17 (18.5) 10 (21.7) 7 (15.2)
 Distal bile duct 42 (45.7) 19 (41.3) 23 (50.0)
 Gallbladder 20 (21.7) 11 (23.9) 9 (19.6)
Histology (%)
 Adenocarcinoma 86 (93.5) 43 (93.5) 43 (93.5) 1.000
 Others 6 (6.5) 3 (6.5) 3 (6.5)
Grade (%)
 Well 4 (4.3) 1 (2.2) 3 (6.5) 0.590
 Moderate 63 (68.5) 32 (69.6) 31 (67.4)
 Poor 21 (22.8) 12 (26.1) 9 (19.6)
 NA 4 (4.3) 1 (2.2) 3 (6.5)
LV invasion (%)
 Yes 64 (69.6) 29 (63.0) 35 (76.1) 0.213
 No 25 (27.2) 15 (32.6) 10 (21.7)
 NA 3 (3.3) 2 (4.3) 1 (2.2)
Perineural invasion (%)
 Yes 65 (70.7) 34 (73.9) 31 (67.4) 0.414
 No 14 (15.2) 9 (19.6) 5 (10.9)
 NA 13 (14.1) 3 (6.5) 10 (21.7)
pT stage (%)
 1 10 (10.9) 3 (6.5) 7 (15.2) 0.279
 2 39 (42.4) 21 (45.7) 18 (39.1)
 3 41 (44.6) 22 (47.8) 19 (41.3)
 4 2 (2.2) 0 (0.0) 2 (4.3)
LN involvement (%)
 Yes 54 (58.7) 26 (56.5) 28 (60.9) 0.672
 No 38 (41.3) 20 (43.5) 18 (39.1)
Pathologic stage (%)
 I 14 (15.2) 5 (10.9) 9 (19.6) 0.611
 II 37 (40.2) 19 (41.3) 18 (39.1)
 III 28 (30.4) 16 (34.8) 12 (26.1)
 IVa 13 (14.1) 6 (13.0) 7 (15.2)
Resection margin (%)
 Negative 45 (48.9) 16 (34.8) 29 (63.0) 0.007
 Positive 47 (51.1) 30 (65.2) 17 (37.0)
CA19–9 (%)
 < 37 U/ml 35 (38.0) 16 (34.8) 19 (41.3) 0.697
 ≥37 U/ml 50 (54.3) 25 (54.3) 25 (54.3)
 NA 7 (7.6) 5 (10.9) 2 (4.3)
Recurrence (%)
 No 19 (20.7) 18 (39.1) 1 (2.2) 0.123
 Locoregional 22 (23.9) 6 (13.0) 16 (34.8)
 Distant 36 (39.1) 13 (28.3) 23 (50.0)
 Both 15 (16.3) 9 (19.6) 6 (13.0)
  1. CCRT Concurrent chemoradiotherapy, KPS Karnofsky performance score, CCI Charlson comorbidity index, LV Lymphovascular, LN Lymph node
  2. aAll patients had M0 status, 10 patients had TxN1M0(IVA) intrahepatic bile duct cancers, and 3 patients had TxN2M0(IVB) GB cancers